- Home
- RCG
RCG
RENN Fund Inc
as 02-21-2025 4:00pm EST
RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, Oil and Gas, medical chemicals, botanical products, and others.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 19.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 5.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | -0.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.52 - $1.90 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of RENN Fund Inc (RCG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| STAHL MURRAY | RCG | President and CEO | Feb 18 '25 | Buy | $2.66 | 1,244 | $3,309.04 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Feb 14 '25 | Buy | $2.60 | 1,244 | $3,234.40 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Feb 13 '25 | Buy | $2.67 | 1,436 | $3,834.12 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Feb 11 '25 | Buy | $2.70 | 1,242 | $3,353.40 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Feb 7 '25 | Buy | $2.68 | 1,244 | $3,333.92 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Feb 6 '25 | Buy | $2.67 | 1,246 | $3,326.82 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Feb 5 '25 | Buy | $2.79 | 1,242 | $3,465.28 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Feb 4 '25 | Buy | $2.80 | 1,240 | $3,472.00 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Feb 3 '25 | Buy | $2.76 | 1,244 | $3,433.44 | 59,162 | |
| STAHL MURRAY | RCG | President and CEO | Jan 31 '25 | Buy | $2.76 | 1,246 | $3,438.96 | 59,162 |
Latest RENN Fund Inc News
RCG Breaking Stock News: Dive into RCG Ticker-Specific Updates for Smart Investing
ACCESSWIRE
2 months ago
RENN Fund, Inc. Announces Year End Distribution
ACCESSWIRE
3 months ago
RENN Fund, Inc. Announces Record Date for Year End Distribution
GlobeNewswire
a year ago
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
InvestorPlace
a year ago
Beware the AI Hype: 3 Stocks to Sell Before They Tumble
GlobeNewswire
a year ago
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
Zacks
a year ago
Gear Up for Washington Trust (WASH) Q4 Earnings: Wall Street Estimates for Key Metrics
Investor's Business Daily
a year ago
Apple Isn't The Only Player In Spatial Computing. Rivals Populated CES 2024.
PR Newswire
a year ago
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
Compare RCG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCG RENN Fund Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.